- The Dish’s Weekly Biotechnology News Wrap Up – April 21, 2017Posted 5 days ago
- Glycosylation Overview and How to Control Glycosylation using In Vitro GlycoengineeringPosted 7 days ago
- A Novel Approach for Expansion of High Quality Mesenchymal Stem CellsPosted 1 week ago
- Cell Therapy Clinical Trials: Navigating the operational shift from Phase 1 to Phase 2Posted 1 week ago
- The Dish’s Weekly Biotechnology News Wrap Up – April 14, 2017Posted 2 weeks ago
- GMP Proteins for Cell Therapy Manufacturing: Top 6 Things to KnowPosted 2 weeks ago
- Smart Cell Culture Monitoring – Transforming the way we look at cells in culturePosted 2 weeks ago
- A Primer on Primary Cells and CulturePosted 2 weeks ago
- The Importance of Resin Selection in Development of a Platform Bioprocess FilmPosted 2 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – April 7, 2017Posted 3 weeks ago
Cool Tool – mAbVault for Antibody Manufacturing: Protect Quality, Minimize Expenses, and Simplify Scale-up
A guest blog by Scott Waniger, Vice President of Bioservices, Biovest International and Erin Rasch, Director of BD, Biovest International
Antibody-based products face three primary demands as they scale from R&D to commercial manufacturing – protect quality, minimize expenses, and simplify scale-up. Since bioreactor production technology factors heavily into addressing these demands, it is critical that each organization thoroughly explores all available manufacturing options. To that end, Biovest has launched mAbVault.
mAbVault is a network of Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) with expertise in hollow fiber bioreactors (HFBR). HFBR is a technology platform that has quietly become known for consistency in yields and quality, minimized start-up costs and seamless scale-up. Learn more about HFBR in this recent Cell Culture Dish article “Hollow Fiber Provides a Sweet Spot for Several Biomanufacturing Applications”.
Challenges with Standard CMO Operations
Technologies employed by most CMOs can be variable in the yield reached and time to reach it. Due to this variability it can be difficult to predict scale-up and protein production costs with accuracy, thus requiring pricing to be based upon time and materials. This type of arrangement leaves the protein owner with an unclear picture of the cost and timeline for their protein production and subsequently they shoulder the majority of the risk.
When it is time for scale-up of the process, another level of risk is introduced as a new manufacturing process and equipment is often required. The implementation of new technology requires costly re-validation time periods and potential issues with product quality changes. In addition, utilizing a single CMO supplier does not fully address redundancy needs and thus protect against unpredictable product shortages.
How mAbVault is Different
mAbVault offers a fixed price for the life of the product, through all regulatory stages, guaranteed. This approach eliminates up-front protein development and technology transfer expenses. Protein owners pay only for delivered product, thus reducing overall production expenses by up to 60% versus ascites, rocking bioreactors and tanks.
mAbVault makes scaling up easy. Production is validated to a single hollow fiber bioreactor cartridge that provides consistent quality and yields. Scaling up consists of adding incremental cartridges in lateral production, with no need to re-validate as you move from mg to kg quantities.
Additional advantages of mAbVault
- Inventory expenses are kept off the books through just-in-time delivery
- mAbVault vetted CMOs are GMP-compliant facilities that employ experts in hollow fiber technology
- Second site production and storage is standard
- Over 1700 organizations served globally and 2700 cell lines expanded – through all stages of regulatory compliance
Take advantage of robust supply chain systems already serving top global therapeutic and diagnostic organizations, please contact the authors with questions or to learn more.
Scott Waniger, Vice President of Bioservices, Biovest International
(763) 786-0302, firstname.lastname@example.org
Scott supervises all operations of Biovest’s Contract Manufacturing Division and mAbVault. He also oversees upstream production at Biovest’s Biologics Manufacturing Division, which supports the manufacturing of Dasiprotimut-T, an autologous adaptive immunotherapy vaccine targeting Indolent Follicular non-Hodgkins Lymphoma. Scott holds a B.S. in Medical Technology (ASCP) from the University of Wisconsin and has been with Biovest since 1989.
Erin Rasch, Director of Business Development, Biovest International
(763) 786-0302, email@example.com
Erin joined Biovest in September 2015. She previously served as Sales Engineer for DCI-Biolafitte, which specializes in bioreactor manufacturing, and as a Manufacturing Process Engineer at Verenium Corporation. Erin holds an M.S. in Bioengineering from the University of California in San Diego and a B.S. in Chemical Engineering from Auburn University.
All bioprocessing professionals are also invited to attend the official mAbVault launch event occurring during the week of the BioProcess International conference in Boston, MA. Details provided below:
Wednesday October 28th, 7:00 – 10:00 PM
Bioprocess Networking Event Hosted by mAbVault
Complimentary Food and Drinks
Dillon’s Bar and Restaurant
955 Boylson St. (1 block from Hynes Convention Center)
*By RSVP only – Space Limited – RSVP at: http://mabvault.eventbrite.com